• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Phibro Animal Health Corporation Completes Acquisition of Zoetis' Medicated Feed Additive Product Portfolio and Certain Water-Soluble Products

    10/31/24 4:10:00 PM ET
    $PAHC
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PAHC alert in real time by email

    Phibro Animal Health Corporation (NASDAQ:PAHC) today announced the successful completion of the acquisition of the medicated feed additive product portfolio and certain water-soluble products from Zoetis Inc. (NYSE:ZTS). This acquisition marks a significant step in furthering Phibro's purpose to optimize global animal health and nutrition for better lives and a more sustainable world.

    "Adding this new lineup of medicated feed additives and water-soluble products across cattle, swine and poultry will complement and expand Phibro's species and product portfolios, helping customers meet the highest standards of animal care, prevent disease, and enhance nutrition around the world," said Jack C. Bendheim, Chairman, President and Chief Executive Officer of Phibro Animal Health Corporation. "These products fit Phibro's core competencies and capabilities while complementing our current lineup of vaccines, nutritional specialties and mineral nutrition."

    The acquisition includes a product portfolio with more than 37 product lines sold across approximately 80 countries, six manufacturing sites in the U.S., Italy and China, and a team of more than 300 employees who primarily support the manufacturing and distribution activities of the business. The agreement to acquire the business was announced on April 28, 2024.

    The portfolio is expected to boost Phibro's profitability and EBITDA margin and be accretive to its Adjusted Earnings Per Share. Additional financial details will be provided during our Q1 earning call on November 7th.

    "This is a win-win-win," noted Larry Miller, Phibro's Chief Operating Officer. "For our customers, it broadens the solution options and expertise that Phibro brings to support animal health globally; for consumers, it helps continue to ensure that food is produced safely and sustainably; and for our investors, it expands and diversifies our revenue base, ultimately generating funding to support future investment in additional fast-growing animal health product categories."

    About Phibro Animal Health Corporation

    Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner with livestock producers, farmers, veterinarians, and consumers who raise or care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. For further information, please visit www.pahc.com.

    Forward-Looking Statements

    DISCLOSURE NOTICES

    Forward-Looking Statements: This communication contains forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical or current fact included in this communication are forward-looking statements. Forward-looking statements discuss our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as "aim," "anticipate," "believe," "estimate," "expect," "forecast," "outlook," "potential," "project," "projection," "plan," "intend," "seek," "may," "could," "would," "will," "should," "can," "can have," "likely," the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. If one or more of these risks or uncertainties materialize, or if management's underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Quarterly Report on Form 10-Q and Annual Report on Form 10-K, including in the sections thereof captioned "Forward-Looking Statements" and "Risk Factors." These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.

    Internet Posting of Information: We routinely post information that may be important to investors in the "Investors" section of our website at www.pahc.com. We encourage investors and potential investors to consult our website regularly for important information about us.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20241031903897/en/

    Get the next $PAHC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What acquisition did Phibro Animal Health Corporation recently complete?

      Phibro Animal Health Corporation announced the acquisition of a medicated feed additive product portfolio from Zoetis, aimed at enhancing its offerings in animal health and nutrition.

    • What does the acquired product portfolio include?

      The acquisition includes over 37 product lines sold in around 80 countries and involves six manufacturing sites in the U.S., Italy, and China.

    • How is the acquisition expected to impact Phibro's financial performance?

      The acquisition is expected to improve Phibro's profitability, EBITDA margin, and be accretive to its Adjusted Earnings Per Share.

    • What are the anticipated benefits of the acquisition as highlighted by Phibro's COO?

      Larry Miller, Phibro's COO, stated that the acquisition expands the solution options for customers, ensures safe and sustainable food production for consumers, and diversifies revenue for investors.

    • When will Phibro provide more financial details about the acquisition?

      Additional financial details regarding the acquisition will be provided during the Q1 earnings call on November 7th.

    Recent Analyst Ratings for
    $PAHC
    $ZTS

    CompanyDatePrice TargetRatingAnalyst
    Zoetis Inc.
    $ZTS
    4/15/2026$145.00Buy
    Citigroup
    Phibro Animal Health Corporation
    $PAHC
    4/15/2026$62.00Neutral
    Citigroup
    Zoetis Inc.
    $ZTS
    1/22/2026$135.00Overweight → Neutral
    Piper Sandler
    Zoetis Inc.
    $ZTS
    12/15/2025$135.00Buy → Neutral
    BofA Securities
    Zoetis Inc.
    $ZTS
    12/9/2025$136.00Equal Weight
    Barclays
    Zoetis Inc.
    $ZTS
    11/21/2025Sector Weight
    KeyBanc Capital Markets
    Zoetis Inc.
    $ZTS
    7/17/2025$155.00Outperform → Market Perform
    Leerink Partners
    Phibro Animal Health Corporation
    $PAHC
    7/7/2025$35.00Neutral → Overweight
    Analyst
    More analyst ratings

    $PAHC
    $ZTS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 13, 2022 - FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species

    For Immediate Release: January 13, 2022 Today, the U.S. Food and Drug Administration approved Solensia (frunevetmab injection), the first treatment for the control of pain associated with osteoarthritis in cats and the first monoclonal antibody (mAb) new animal drug approved by the FDA for use in any animal species.  Frunevetmab, the active ingredient in Solensia, is a cat-specific monoclonal antibody (a type o

    1/13/22 10:26:13 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Zoetis with a new price target

    Citigroup initiated coverage of Zoetis with a rating of Buy and set a new price target of $145.00

    4/15/26 8:10:45 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Phibro Animal Health with a new price target

    Citigroup initiated coverage of Phibro Animal Health with a rating of Neutral and set a new price target of $62.00

    4/15/26 8:10:03 AM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Zoetis from Overweight to Neutral and set a new price target of $135.00

    1/22/26 8:26:41 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on May 7, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurtur

    4/2/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Participate in the KeyBanc Capital Markets Healthcare Forum

    Zoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 10:30 a.m. ET. Interested parties can access the live audio webcast of the presentation by visiting https://investor.zoetis.com/events-presentations. A replay will also be available on the Zoetis website at the conclusion of the event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, an

    3/12/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis to Participate in Upcoming Investor Conferences

    Zoetis Inc. (NYSE:ZTS) today announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will participate in fireside chats at the following investor conferences. Leerink Global Healthcare Conference on Monday, March 9, 2026 at 3:00 p.m. ET Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026 at 9:30 a.m. ET Interested parties can access live audio webcasts of the presentations by visiting https://investor.zoetis.com/events-presentations. Replays will also be available on the Zoetis website at the conclusion of each event. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our

    3/5/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    SEC Filings

    View All

    Phibro Animal Health Corporation filed SEC Form 8-K: Leadership Update

    8-K - PHIBRO ANIMAL HEALTH CORP (0001069899) (Filer)

    4/14/26 4:15:29 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Zoetis Inc.

    DEF 14A - Zoetis Inc. (0001555280) (Filer)

    4/8/26 9:01:42 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEFA14A filed by Zoetis Inc.

    DEFA14A - Zoetis Inc. (0001555280) (Filer)

    4/8/26 9:02:53 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Corcoran E Thomas bought $110,500 worth of shares (5,000 units at $22.10), increasing direct ownership by 20% to 30,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    2/26/25 4:15:17 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Corcoran E Thomas bought $100,100 worth of shares (5,000 units at $20.02), increasing direct ownership by 25% to 25,000 units (SEC Form 4)

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    9/6/24 4:34:30 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

    SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/15/24 4:15:40 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/14/24 12:51:31 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Phibro Animal Health Corporation

    SC 13G/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/12/24 4:55:22 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    Financials

    Live finance-specific insights

    View All

    Zoetis to Host Webcast and Conference Call on First Quarter 2026 Financial Results

    Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review first quarter 2026 financial results and respond to questions from financial analysts. Investors and the public may access the live webcast and corresponding slides by visiting the Zoetis website at https://investor.zoetis.com/events-presentations. Pre-registration for the webcast is available beginning today. A replay will be made available on May 7, 2026. About Zoetis Zoetis is the world's leading animal health company, driven by a singular purpose: to nurtur

    4/2/26 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Reports Fourth Quarter and Full Year 2025 Results

    Reports Revenue of $2.4 Billion, Growing 3%, and Net Income of $603 Million, or $1.37 per Diluted Share, Increasing 4% and 6%, Respectively, on a Reported Basis for Fourth Quarter 2025 Delivers 4% Organic Operational Growth in Revenue and 4% Organic Operational Growth in Adjusted Net Income for Fourth Quarter 2025 Reports Adjusted Net Income of $648 Million, or Adjusted Diluted EPS of $1.48, for Fourth Quarter 2025 Reports Revenue of $9.5 Billion, Growing 2%, and Net Income of $2.7 Billion, or $6.02 per Diluted Share, Increasing 8% and 10%, Respectively, on a Reported Basis for Full Year 2025 Delivers 6% Organic Operational Growth in Revenue and 7% Organic Operational Growth i

    2/12/26 7:00:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Declares Second Quarter 2026 Dividend

    The Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's common stock as of the close of business on Monday, April 20, 2026. About Zoetis As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock producers. The com

    2/5/26 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    Leadership Updates

    Live Leadership Updates

    View All

    Phibro Animal Health Corporation Announces Leadership Transition

    Jack Bendheim to Assume the Role of Executive Chairman; Daniel Bendheim Named Chief Executive Officer and President Phibro Animal Health Corporation (NASDAQ:PAHC) (the "Company" or "Phibro") today announced a leadership transition that will support the Company's continued growth and long-term strategic direction. At the end of this fiscal year, effective July 1, 2026, Jack Bendheim, current Chairman, Chief Executive Officer and President of Phibro will take on a new managerial role as Executive Chairman and Daniel (Dani) Bendheim will assume the role of Chief Executive Officer and President of Phibro. Jack Bendheim will continue to serve as the Chairman of the Board of Directors of the Com

    12/18/25 4:10:00 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026

    Dr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career dedicated to advancing veterinary medicine and innovation, Rob Polzer, Ph.D., Executive Vice President and President, Research and Development, has made the personal decision to retire at the end of 2025. After a planful succession process, Zoetis has appointed Kevin Esch, D.V.M, M.P.H., Ph.D., Dipl. ACVP (anatomic) to succeed Dr. Polzer in this role, effective January 1, 2026. Dr. Esch currently serves as Senior Vice President of Global Therapeutics at Zoetis and joined Zoe

    11/3/25 4:15:00 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Zoetis Appoints Stephanie Tilenius to its Board of Directors

    Health entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as of December 1, 2025. Ms. Tilenius brings extensive experience in technology-forward, digital health organizations to the Zoetis Board. Ms. Tilenius is a serial entrepreneur and has founded several healthcare companies, including most recently a stealth company in the longevity AI space. Previously, she founded Vida Health, Inc., a leading B2B chronic care platform focusing on diabetes and obesity, and scaled it nationally for Fortune 500 companies, large payers and healthcar

    10/28/25 8:30:00 AM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PAHC
    $ZTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bendheim Jack

    4 - PHIBRO ANIMAL HEALTH CORP (0001069899) (Issuer)

    4/16/26 8:25:42 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fuller Julie

    4 - Zoetis Inc. (0001555280) (Issuer)

    4/13/26 6:02:46 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lagano Roxanne

    4 - Zoetis Inc. (0001555280) (Issuer)

    4/13/26 6:02:40 PM ET
    $ZTS
    Biotechnology: Pharmaceutical Preparations
    Health Care